Literature DB >> 28180235

Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome.

Walter Ageno1, Francesco Dentali, Fulvio Pomero, Luigi Fenoglio, Alessandro Squizzato, Giovanni Pagani, Roberta Re, Matteo Bonzini.   

Abstract

Little information is available on the incidence of splanchnic vein thrombosis and on mortality rates during the acute phase of the disease. We performed a large epidemiologic study on hospital admissions for portal vein thrombosis (PVT) and the Budd-Chiari syndrome (BCS) between 2002 and 2012 in Northwestern Italy. Primary and secondary discharge diagnoses of PVT and BCS were identified using the 9th edition International Classification of Diseases codes 453.0, 572.1 and 452. Hospitalisations for recurrent events were not included. Information was collected on age and gender, vital status at discharge, duration of hospitalisation, and up to five secondary discharge diagnoses. Comorbidity was evaluated using the Charlson comorbidity index (CCI). A total of 3535 patients with PVT and 287 with BCS were hospitalized. The overall gender-specific incidence rates for PVT were 3.78 per 100,000 inhabitants in males and 1.73 per 100,000 inhabitants in females; for BCS 2.0 and 2.2 per million inhabitants, respectively. In-hospital case fatality was 7.3 % in patients with PVT and 4.9 % in patients with BCS. Age, non-abdominal solid cancer, and CCI were independently associated with in-hospital mortality in both PVT and BCS after stepwise regression analysis, male gender and haematologic cancer were associated with mortality in BCS patients only. In this large study we confirmed the low incidence of BCS and we found an incidence of PVT higher than previously reported. This incidence was stable during the period of observation. In-hospital mortality is not negligible, in particular in PVT patients.

Entities:  

Keywords:  Budd-Chiari syndrome; Portal vein thrombosis; epidemiology; mortality

Mesh:

Year:  2017        PMID: 28180235     DOI: 10.1160/TH16-10-0781

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

Review 1.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

2.  Risk Factors, Clinical Presentation, Diagnosis, and Treatment Outcomes of Portal Vein Thrombosis: A Five-Year Hospital-Based Study From Qatar.

Authors:  Fahmi Yousef Khan; Elmukhtar Habas; Theeb Osama Sulaiman; Omnia A Hamid; Ahmed Abdalhadi; Ahmad Khalaf; Mohammed S Afana; Mohamed Yousif Ali; Yahia Zakaria Baniamer; Wael Kanjo; Bassam Muthanna; Raza Ali Akbar
Journal:  J Clin Med Res       Date:  2022-05-31

3.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

Review 4.  Tailored classification of portal vein thrombosis for liver transplantation: Focus on strategies for portal vein inflow reconstruction.

Authors:  Fei Teng; Ke-Yan Sun; Zhi-Ren Fu
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

5.  Hypoxia-inducible Factor may Induce the Development of Liver Fibrosis in Budd-Chiari Syndrome by Regulating CD248/endosialin Expression: A Hypothesis.

Authors:  Ye Tian; Han Deng; Lei Han; Sijun Hu; Xingshun Qi
Journal:  J Transl Int Med       Date:  2018-06-26

6.  Japanese periodical nationwide epidemiologic survey of aberrant portal hemodynamics.

Authors:  Satoko Ohfuji; Yoshihiro Furuichi; Tomohiko Akahoshi; Masayoshi Kage; Katsutoshi Obara; Makoto Hashizume; Tomoka Matsuura; Wakaba Fukushima; Yosikazu Nakamura
Journal:  Hepatol Res       Date:  2019-04-25       Impact factor: 4.288

Review 7.  Splanchnic Vein Thrombosis: Current Perspectives.

Authors:  Emanuele Valeriani; Nicoletta Riva; Marcello Di Nisio; Walter Ageno
Journal:  Vasc Health Risk Manag       Date:  2019-10-22

Review 8.  Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  J Clin Med       Date:  2020-03-10       Impact factor: 4.241

9.  Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.

Authors:  Helen J Mayfield; Colleen L Lau; Jane E Sinclair; Samuel J Brown; Andrew Baird; John Litt; Aapeli Vuorinen; Kirsty R Short; Michael Waller; Kerrie Mengersen
Journal:  Vaccine       Date:  2022-04-08       Impact factor: 4.169

10.  Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data.

Authors:  Luigi Cari; Paolo Fiore; Mahdieh Naghavi Alhosseini; Gianni Sava; Giuseppe Nocentini
Journal:  J Autoimmun       Date:  2021-06-23       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.